ClinicalTrials.gg
RecruitingNCT05748015Updated Apr 17, 2026

Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis

An interventional study of quantification of sensory and autonomic small nerve fibers by punch skin biopsy and Cardiovascular Reflexes testing in Multiple Sclerosis, sponsored by Istituti Clinici Scientifici Maugeri SpA. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Istituti Clinici Scientifici Maugeri SpA · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Mar 2021, registered Jan 2023).
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 289 studies in Multiple Sclerosis with a site in Italy — 59 open to participants now, 90 under way, 13 of them phase 3. Multiple Sclerosis · Italy.

Planned enrollment
141st of 230
60 · median 115
Started
2021
with 22 others
No phase
105 of 289
33 open now
Primary completion
2026-11
later than 56 of 89 live
Registered
206th of 289
by date

Among the 289 studies in Multiple Sclerosis with a site in Italy, this one is the 141st largest by planned enrollment of the 230 interventional ones that give a count, is one of 23 that started in 2021, is one of 105 with no phase, reaches primary completion later than 56 of the 89 other live ones, and was the 206th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

59 of the 289 studies in Multiple Sclerosis with a site in Italy are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 289 studies in Multiple Sclerosis with a site in Italy, or all of them as a file.
02

Study summary

The goal of this interventional non-pharmacological study is to evaluate the involvement of the autonomic nervous system in patients with relapsing-remitting and primary progressive multiple sclerosis.

The main questions it aims to answer are:

  • Is it possible to define the characteristics of dysautonomia to improve treatment on patients with multiple sclerosis through the management of conditions such as orthostatic hypotension or thermoregulation disorders that inevitably condition the patient's life and the response to rehabilitation ?
  • Does the severity of the functional alterations correlate with impairment of small somatic and autonomic cutaneous nerve fibers in patients with multiple sclerosis ?
  • How much the involvement of the autonomic nervous system affects the clinical history and progression of the disease ?
  • Do different clinical variants of multiple sclerosis manifest with different patterns of involvement of the sensory-autonomic nervous system ?

Participants will be hospitalized in Maugeri Clinical Institute of Telese Terme for a rehabilitation treatment. Patients will perform a sensory and autonomic functional study and a morphological analysis of cutaneous nerves through skin biopsy.

Researchers will compare results between the two groups (relapsing-remitting and primary progressive) and between patients and data from control subjects.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • autonomic nervous system
  • sensory nervous system
  • rehabilitation
  • skin biopsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of relapsing-remitting and primary progressive multiple sclerosis.

Exclusion criteria

Exclusion Criteria:

  • other forms of multiple sclerosis,
  • known other neurological disorders
  • assumption of potentially neurotoxic substances or drugs.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    relapsing-remitting multiple sclerosis

    Patients with relapsing-remitting multiple sclerosis will be hospitalized in Maugeri Clinical Institute of Telese Terme for a rehabilitation treatment and will perform a functional and morphological study of sensory and autonomic nervous system, evaluation of peripheral sensory and autonomic nerve fibers performed by skin biopsy.

    Diagnostic Test: quantification of sensory and autonomic small nerve fibers by punch skin biopsy · Diagnostic Test: Cardiovascular Reflexes testing · Other: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms

  • Active comparator
    primary progressive multiple sclerosis

    Patients with primary progressive multiple sclerosis will be hospitalized in Maugeri Clinical Institute of Telese Terme for a rehabilitation treatment and will perform a functional and morphological study of sensory and autonomic nervous system, evaluation of peripheral sensory and autonomic nerve fibers performed by skin biopsy.

    Diagnostic Test: quantification of sensory and autonomic small nerve fibers by punch skin biopsy · Diagnostic Test: Cardiovascular Reflexes testing · Other: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms

Interventions

  • Diagnostic testquantification of sensory and autonomic small nerve fibers by punch skin biopsy

    We'll perform a punch skin biopsy of 3mm from thigh, leg and fingertip and we'll quantify peripheral sensory and autonomic nerve fibers.

  • Diagnostic testCardiovascular Reflexes testing

    Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.

  • OtherAdministration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms

    We'll characterize patients' symptoms through the administration of clinical scales such as: COMPASS 31 autonomic symptoms scale; Small Fiber Neuropathy Symptom Inventory Questionnaire (SFN-SIQ), the Pain Detect Questionnaire and the Total neuropathy score

06

What researchers measure

Primary outcomes

  1. Cardiovascular reflex test

    Assessment of Cardiovascular reflex responses to physical challenges.

    Time frame: At the recruitment

  2. Sudomotor function test

    Assessment of postganglionic sudomotor function through dynamic sweat test

    Time frame: At the recruitment

Secondary outcomes

  1. Quantification of peripheral autonomic nerve fibers

    Quantification of sweat gland innervation (fiber length /um3) and arrector pili muscle (ff/mm).

    Time frame: At the recruitment

  2. Quantification of peripheral sensory nerve fibers

    Quantification of sensory nerve fibers (Intraepidermal nerve fibers (ff/mm)).

    Time frame: At the recruitment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Mahoney CJ, Ahmed RM, Huynh W, Tu S, Rohrer JD, Bedlack RS, Hardiman O, Kiernan MC. Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. CNS Drugs. 2021 May;35(5):483-505. doi: 10.1007/s40263-021-00820-1. Epub 2021 May 15. PubMed 33993457 ↗
  • Gentile F, Scarlino S, Falzone YM, Lunetta C, Tremolizzo L, Quattrini A, Riva N. The Peripheral Nervous System in Amyotrophic Lateral Sclerosis: Opportunities for Translational Research. Front Neurosci. 2019 Jun 25;13:601. doi: 10.3389/fnins.2019.00601. eCollection 2019. PubMed 31293369 ↗
  • Weis J, Katona I, Muller-Newen G, Sommer C, Necula G, Hendrich C, Ludolph AC, Sperfeld AD. Small-fiber neuropathy in patients with ALS. Neurology. 2011 Jun 7;76(23):2024-9. doi: 10.1212/WNL.0b013e31821e553a. PubMed 21646630 ↗
  • Truini A, Biasiotta A, Onesti E, Di Stefano G, Ceccanti M, La Cesa S, Pepe A, Giordano C, Cruccu G, Inghilleri M. Small-fibre neuropathy related to bulbar and spinal-onset in patients with ALS. J Neurol. 2015;262(4):1014-8. doi: 10.1007/s00415-015-7672-0. Epub 2015 Feb 17. PubMed 25683764 ↗
  • Nolano M, Provitera V, Manganelli F, Iodice R, Caporaso G, Stancanelli A, Marinou K, Lanzillo B, Santoro L, Mora G. Non-motor involvement in amyotrophic lateral sclerosis: new insight from nerve and vessel analysis in skin biopsy. Neuropathol Appl Neurobiol. 2017 Feb;43(2):119-132. doi: 10.1111/nan.12332. Epub 2016 Jul 7. PubMed 27288647 ↗
  • deCarvalho M, Gromicho M, Andersen P, Grosskreutz J, Kuzma-Kozakiewicz M, Petri S, Uysal H, Pinto S. Peripheral neuropathy in ALS: phenotype association. J Neurol Neurosurg Psychiatry. 2021 Oct;92(10):1133-1134. doi: 10.1136/jnnp-2020-325164. Epub 2020 Dec 28. No abstract available. PubMed 33372053 ↗
  • Chio A, Mora G, Lauria G. Pain in amyotrophic lateral sclerosis. Lancet Neurol. 2017 Feb;16(2):144-157. doi: 10.1016/S1474-4422(16)30358-1. Epub 2016 Dec 8. PubMed 27964824 ↗
  • Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. doi: 10.1080/146608200300079536. No abstract available. PubMed 11464847 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Nov 2026, 68 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 68 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2023
First posted
Feb 28, 2023
StartActual
Mar 4, 2021
Primary completionEst.
Nov 30, 2026
CompletionEst.
May 30, 2027
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05748015
Responsible party
Sponsor
First posted
Feb 28, 2023
Start date
Mar 4, 2021
Primary completion
Nov 30, 2026 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Apr 17, 2026

Study contacts

Vincenzo Provitera, MD
Contact
vincenzo.provitera@icsmaugeri.it
+390824909257
Giuseppe Caporaso
Contact
giuseppe.caporaso@icsmaugeri.it
+390824909645
Vincenzo Provitera, MD
principal investigator · ICS MAUGERI - IRCCS TELESE TERME

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion